Advanced Renal Cell Carcinoma: Combination, Sequential Strategies, & Immunotherapy
The advent of targeted therapies has significantly transformed outcomes for patients with renal cell carcinoma (RCC). Despite improvements in response and survival seen in the first-line setting with these agents for advanced RCC, progression/relapse is very common and most patients require second, third or further lines of therapy. Clinicians managing advanced RCC are challenged by a variety of factors, including the need to keep up with new data on all treatment options, select therapies on an individual case basis, use the optimal sequence or combination of therapies, and effectively manage side effects of all agents.
This activity is intended for US-based oncologists, NPs, urologists and other healthcare professionals involved in treating patients with renal cell carcinoma.
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research Associate Professor
Department of Hematology/Oncology
Fox Chase Cancer Center
Daniel M. Geynisman, MD
Genitourinary Medical Oncology
Department of Hematology/Oncology
Fox Chase Cancer Center
DISCLOSURE POLICY: In accordance with the ACCME Standards for Commercial Support, The National Comprehensive Cancer Network (NCCN) and The France Foundation (TFF) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. NCCN and TFF resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, NCCN and TFF seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. NCCN and TFF are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
ACTIVITY STAFF DISCLOSURES: The planners, reviewers, editors, staff, CME committee, or other members at NCCN who control content have no relevant financial relationships to disclose. The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.
FACULTY DISCLOSURES−CONTENT CREATORS: The following faculty report that they have relevant financial relationships to disclose:
- Dr. Eric Jonasch has received grants for research support from Exelixis, Novartis, and Pfizer. He serves as a consultant for Bristol-Myers Squibb, Eisai, Exelixis, Novartis, and Pfizer.
- Dr. Robert J. Motzer has received grants for research support from Bristol-Myers Squibb, Exelixis, Genentech/Roche, Novartis and Pfizer. He serves as a consultant for Eisai, Exelixis, Novartis and Pfizer.
- Dr. Elizabeth R. Plimack has received grants for research support from Acceleron, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Novartis, Merck, Peloton and Pfizer. She serves as a consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Exelixis, Genentech, Novartis, Pfizer and Roche.
FACULTY DISCLOSURES−ACTIVITY FACULTY: The following faculty report that they have relevant financial relationships to disclose:
- Dr. Daniel Geynisman serves as a consultant for Exelixis, Novartis and Pfizer.
DISCLOSURE OF UNLABELED USE: NCCN and TFF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. NCCN and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
DISCLAIMER: NCCN and TFF present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. NCCN, The France Foundation, Bristol-Myers Squibb, Eisai, Exelixis, and Novartis assume no liability for the information herein.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hour.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.
- 1.00 ANCC contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Upon completion of this course, the participants should be able to:
- Review clinical data on established and emerging therapies for patients with advanced RCC
- Assess sequential treatment strategies and combination therapies for patients with advanced RCC
- Examine selection of optimal therapy based on patient characteristics and prior treatment history
- Evaluate strategies for management of side effects associated with therapies for advanced RCC